Search research articles
Contact Us
Filters
Showing results (41-50 of 60) with videos related to
Page
of 6
Sort By:
Clinical Pharmacology in Drug Development
|
April 20, 2026
Effects of Cedirogant on the Pharmacokinetics of Sensitive Cytochrome P450 Probe Substrates
Ronilda D'Cunha, Yuli Qian, Shuai Hao, et al.
Cancer Immunology Research
|
November 8, 2018
PARP1 Suppresses the Transcription of PD-L1 by Poly(ADP-Ribosyl)ating STAT3
Ling Ding, Xi Chen, Xiaqing Xu, et al.
Frontiers in Endocrinology
|
May 16, 2022
Effect of lncRNA MALAT1 on the Granulosa Cell Proliferation and Pregnancy Outcome in Patients With PCOS
Mixue Tu, Yiqing Wu, Feixia Wang, et al.
Frontiers in Endocrinology
|
August 28, 2020
The Association Between Previous TORCH Infections and Pregnancy and Neonatal Outcomes in IVF/ICSI-ET: A Retrospective Cohort Study
Yifeng Liu, Yiqing Wu, Feixia Wang, et al.
Clinical Pharmacology and Therapeutics
|
August 5, 2024
Coproporphyrin-I as a Selective OATP1B Biomarker Can Be Used to Delineate the Mechanisms of Complex Drug-Drug Interactions: Cedirogant Case Study
Ryota Kikuchi, Yuli Qian, Mohamed Badawi, et al.
Clinical Therapeutics
|
August 14, 2024
Pharmacokinetics, Safety, Tolerability, and Exploratory Efficacy of Upadacitinib in Children with Severe Atopic Dermatitis
Yuli Qian, Eliza M Raymundo, Shuai Hao, et al.
Arthritis Care & Research
|
November 14, 2024
Pharmacokinetics, Efficacy, and Safety of Upadacitinib in Pediatric Patients With Polyarticular-Course Juvenile Idiopathic Arthritis: An Interim Analysis of an Open-Label, Phase 1 Trial
Hermine I Brunner, Anna Shmagel, Gerd Horneff, et al.
Clinical and Experimental Dermatology
|
May 3, 2024
Cedirogant in adults with psoriasis: a phase II, randomized, placebo-controlled clinical trial
Stephen Tyring, Angela Moore, Akimchi Morita, et al.
Mbio
|
July 27, 2017
Polymyxin Combinations Combat <i>Escherichia coli</i> Harboring <i>mcr-1</i> and <i>bla</i><sub>NDM-5</sub>: Preparation for a Postantibiotic Era
Zackery P Bulman, Liang Chen, Thomas J Walsh, et al.
Clinical and Translational Science
|
October 27, 2021
Effect of renal impairment on the pharmacokinetics and safety of dorzagliatin, a novel dual-acting glucokinase activator
Jia Miao, Ping Fu, Shuang Ren, et al.
Page
of 6
Search research articles
Search
Showing results (41-50 of 60) with videos related to
Sort By:
Page
of 6
Clinical Pharmacology in Drug Development
|
April 20, 2026
Effects of Cedirogant on the Pharmacokinetics of Sensitive Cytochrome P450 Probe Substrates
Ronilda D'Cunha, Yuli Qian, Shuai Hao, et al.
Cancer Immunology Research
|
November 8, 2018
PARP1 Suppresses the Transcription of PD-L1 by Poly(ADP-Ribosyl)ating STAT3
Ling Ding, Xi Chen, Xiaqing Xu, et al.
Frontiers in Endocrinology
|
May 16, 2022
Effect of lncRNA MALAT1 on the Granulosa Cell Proliferation and Pregnancy Outcome in Patients With PCOS
Mixue Tu, Yiqing Wu, Feixia Wang, et al.
Frontiers in Endocrinology
|
August 28, 2020
The Association Between Previous TORCH Infections and Pregnancy and Neonatal Outcomes in IVF/ICSI-ET: A Retrospective Cohort Study
Yifeng Liu, Yiqing Wu, Feixia Wang, et al.
Clinical Pharmacology and Therapeutics
|
August 5, 2024
Coproporphyrin-I as a Selective OATP1B Biomarker Can Be Used to Delineate the Mechanisms of Complex Drug-Drug Interactions: Cedirogant Case Study
Ryota Kikuchi, Yuli Qian, Mohamed Badawi, et al.
Clinical Therapeutics
|
August 14, 2024
Pharmacokinetics, Safety, Tolerability, and Exploratory Efficacy of Upadacitinib in Children with Severe Atopic Dermatitis
Yuli Qian, Eliza M Raymundo, Shuai Hao, et al.
Arthritis Care & Research
|
November 14, 2024
Pharmacokinetics, Efficacy, and Safety of Upadacitinib in Pediatric Patients With Polyarticular-Course Juvenile Idiopathic Arthritis: An Interim Analysis of an Open-Label, Phase 1 Trial
Hermine I Brunner, Anna Shmagel, Gerd Horneff, et al.
Clinical and Experimental Dermatology
|
May 3, 2024
Cedirogant in adults with psoriasis: a phase II, randomized, placebo-controlled clinical trial
Stephen Tyring, Angela Moore, Akimchi Morita, et al.
Mbio
|
July 27, 2017
Polymyxin Combinations Combat <i>Escherichia coli</i> Harboring <i>mcr-1</i> and <i>bla</i><sub>NDM-5</sub>: Preparation for a Postantibiotic Era
Zackery P Bulman, Liang Chen, Thomas J Walsh, et al.
Clinical and Translational Science
|
October 27, 2021
Effect of renal impairment on the pharmacokinetics and safety of dorzagliatin, a novel dual-acting glucokinase activator
Jia Miao, Ping Fu, Shuang Ren, et al.
Page
of 6